HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2011 | 426 | 508 | 83.9% | |
| HF 4 | 2012 | 461 | 535 | 86.2% | |
| HF 4 | 2013 | 470 | 521 | 90.2% | |
| HF004 | 2014 | 201 | 209 | 96.2% | |
| HF004 | 2015 | 204 | 212 | 96.2% | |
| HF004 | 2016 | 224 | 237 | 94.5% | |
| HF004 | 2017 | 315 | 330 | 95.5% | |
| HF004 | 2018 | 367 | 390 | 94.1% | |
| HF004 | 2019 | 593 | 620 | 95.6% | |
| HF004 | 2020 | 581 | 615 | 94.5% |
